A claims-based analysis of secondary progressive multiple sclerosis (SPMS): Prevalence, demographics, and costs

Secondary progressive multiple sclerosis (SPMS) is a disabling multiple sclerosis phenotype marked by relentlessly progressing neurologic disability. At the time of this analysis, there were no therapies approved by the Food and Drug Administration for SPMS with a manageable risk-benefit ratio. This paper examines the prevalence, demographics, and healthcare cost of SPMS patients.

This article was commissioned by Novartis Pharmaceuticals Corporation.